Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044485940> ?p ?o ?g. }
- W2044485940 endingPage "030" @default.
- W2044485940 startingPage "017" @default.
- W2044485940 abstract "There has been a welcome increase in the number of agents available for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). Vancomycin remains an acceptable treatment option, with moves toward individualized dosing to a pharmacokinetic/pharmacodynamic (PK/PD) target. Numerous practicalities, however, would need to be resolved before implementation. Lipoglycopeptides as a class show excellent in vitro potency. Their long half-lives and complex PKs may preclude these agents being used in critically ill patients. Anti-MRSA cephalosporins provide great promise in the treatment of MRSA. These agents, despite broad-spectrum activity, should be reserved for patients with MRSA infections as it is likely that usage will be associated with increased rates of resistance. Daptomycin is currently the only antibiotic to have shown noninferiority to vancomycin in the treatment of MRSA bacteremia. The results of an open-labeled trial to address the superiority of daptomycin compared with vancomycin in reduced vancomycin susceptibility infections are eagerly anticipated. No drug to date has shown superiority to vancomycin in the treatment of MRSA infections with the possible exception of linezolid in hospital-acquired pneumonia (HAP), making linezolid an important option in the treatment of MRSA-proven HAP. Whether these strengths and features are agent or class specific are unclear but will likely be answered with the marketing of tedizolid. There are insufficient data to recommend either quinupristin/dalfopristin or tigecycline, as first line in the treatment of severe MRSA infections. These agents however remain options in patients with no other alternatives." @default.
- W2044485940 created "2016-06-24" @default.
- W2044485940 creator A5023103534 @default.
- W2044485940 creator A5063456676 @default.
- W2044485940 creator A5074189743 @default.
- W2044485940 creator A5077775016 @default.
- W2044485940 date "2015-02-02" @default.
- W2044485940 modified "2023-09-27" @default.
- W2044485940 title "Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond" @default.
- W2044485940 cites W1529101966 @default.
- W2044485940 cites W1838748187 @default.
- W2044485940 cites W1844631518 @default.
- W2044485940 cites W1867064160 @default.
- W2044485940 cites W1892658174 @default.
- W2044485940 cites W1917119829 @default.
- W2044485940 cites W1965508676 @default.
- W2044485940 cites W1966644699 @default.
- W2044485940 cites W1969798675 @default.
- W2044485940 cites W1970058753 @default.
- W2044485940 cites W1971251009 @default.
- W2044485940 cites W1972470346 @default.
- W2044485940 cites W1977420953 @default.
- W2044485940 cites W1977578039 @default.
- W2044485940 cites W1981151731 @default.
- W2044485940 cites W1982356893 @default.
- W2044485940 cites W1984297262 @default.
- W2044485940 cites W1989051318 @default.
- W2044485940 cites W1994342215 @default.
- W2044485940 cites W1995410390 @default.
- W2044485940 cites W1995489787 @default.
- W2044485940 cites W1995854195 @default.
- W2044485940 cites W1996945472 @default.
- W2044485940 cites W2001604291 @default.
- W2044485940 cites W2002249283 @default.
- W2044485940 cites W2004176560 @default.
- W2044485940 cites W2006458380 @default.
- W2044485940 cites W2009123817 @default.
- W2044485940 cites W2010066166 @default.
- W2044485940 cites W2014711725 @default.
- W2044485940 cites W2016237081 @default.
- W2044485940 cites W2017088525 @default.
- W2044485940 cites W2017411933 @default.
- W2044485940 cites W2019082252 @default.
- W2044485940 cites W2020962641 @default.
- W2044485940 cites W2022265152 @default.
- W2044485940 cites W2023705805 @default.
- W2044485940 cites W2024175754 @default.
- W2044485940 cites W2031250450 @default.
- W2044485940 cites W2031499715 @default.
- W2044485940 cites W2031570656 @default.
- W2044485940 cites W2032335689 @default.
- W2044485940 cites W2036173518 @default.
- W2044485940 cites W2038194207 @default.
- W2044485940 cites W2039989497 @default.
- W2044485940 cites W2041050715 @default.
- W2044485940 cites W2042407830 @default.
- W2044485940 cites W2045190713 @default.
- W2044485940 cites W2045768636 @default.
- W2044485940 cites W2047649930 @default.
- W2044485940 cites W2047888313 @default.
- W2044485940 cites W2050135536 @default.
- W2044485940 cites W2051693645 @default.
- W2044485940 cites W2052608732 @default.
- W2044485940 cites W2057909358 @default.
- W2044485940 cites W2059933629 @default.
- W2044485940 cites W2062793994 @default.
- W2044485940 cites W2062845481 @default.
- W2044485940 cites W2069153240 @default.
- W2044485940 cites W2070689017 @default.
- W2044485940 cites W2073090965 @default.
- W2044485940 cites W2075916622 @default.
- W2044485940 cites W2077228024 @default.
- W2044485940 cites W2077657970 @default.
- W2044485940 cites W2078065191 @default.
- W2044485940 cites W2082441919 @default.
- W2044485940 cites W2083836518 @default.
- W2044485940 cites W2087451437 @default.
- W2044485940 cites W2087663721 @default.
- W2044485940 cites W2087865186 @default.
- W2044485940 cites W2090534172 @default.
- W2044485940 cites W2092084708 @default.
- W2044485940 cites W2094272037 @default.
- W2044485940 cites W2094418371 @default.
- W2044485940 cites W2094442395 @default.
- W2044485940 cites W2096763392 @default.
- W2044485940 cites W2096996011 @default.
- W2044485940 cites W2097083775 @default.
- W2044485940 cites W2097397850 @default.
- W2044485940 cites W2101331380 @default.
- W2044485940 cites W2104589256 @default.
- W2044485940 cites W2104747240 @default.
- W2044485940 cites W2104779095 @default.
- W2044485940 cites W2105533730 @default.
- W2044485940 cites W2106935542 @default.
- W2044485940 cites W2108433768 @default.
- W2044485940 cites W2108742677 @default.
- W2044485940 cites W2108797565 @default.
- W2044485940 cites W2109915370 @default.